Pain is associated with reduced adherence to safer injection practices among people who inject opioids Authors: O Trent Hall, John A Sturgeon, Jasmin Bradley, Abigail Helm, Johnathan Rausch, Emma Kuloszewski, Megan Deaner, Carlos Malvestutto, Ashley Lipps, Afton Hassett Published: 2026 ABSTRACT AbstractBackgroundInjection opioid use is associated with fatal and non-fatal harms including accidental overdose and infectious diseases. Syringe service programs offer sterile injection equipment and safer injection training to reduce the incidence of injection-related harms. Nevertheless, factors that might reduce adherence to safer injection practices are understudied. This report explores pain as one such factor.MethodsPeople who inject opioids (n = 130) were recruited from a syringe service program for a cross-sectional survey assessing the relationship between fluctuations in pain severity and adherence to safer injection practices over the past 7 days.ResultsA within-subjects Sign Test analysis revealed participants’ adherence to safer injection practices fluctuated with changes in pain severity. When their pain was at its worst, participants reported they less often engaged in hand washing (Z −5.63, P < .001), cleaning the injection site (Z −5.29, P < .001), and waiting until in a clean safe place to inject (Z −3.94, P < .001). Additionally, they more often reused their own injection equipment (Z −2.55, P = .011), and injected faster, or at a higher dose (Z −2.71, P = .007) when in worse pain.ConclusionsThis study provides initial evidence that pain is associated with reduced adherence to safer injection practices among people who inject opioids. Although all study participants received training in safer injection practices and cost-free sterile injection equipment, within-subject adherence to safer use practices varied significantly under conditions of best and worst pain.Keywords: Harm reduction, Needle-exchange programs, Risk behaviors, Safer injection practices, Opioid-related disorders, Pain Introduction Injection opioid use—defined as subcutaneous (SQ), intramuscular (IM), or intravenous (IV) injection of opioids such as fentanyl or heroin—is associated with a variety of adverse health outcomes [17, 18, 33]. It has been estimated that 14.8 million people are engaged in injection drug use globally [18]. People who inject drugs, including people who inject opioids, are at risk of accidental overdose and life-threatening infections [17]. A recent meta-analysis estimated 3.2 million people who inject drugs had experienced at least one overdose in the previous year [10]. In the United States, nearly 80,000 people died of fatal drug overdose in 2024 and opioids were involved in nearly 70% of these deaths [23]. Recent analyses suggest that while opioid-smoking-related deaths now outnumber injection-related opioid overdoses, tens of thousands of overdose deaths are injection-related each year [26, 49]. Infectious complications of injection drug use may include soft tissue infections, sepsis, endocarditis, osteomyelitis, spinal epidural abscess, human immunodeficiency virus / acquired immunodeficiency syndrome (HIV/AIDS), and viral hepatitis (hepatitis B and hepatitis C viruses) (HBV and HCV) [33, 34]. Fifteen percent of people who inject are believed to be living with HIV and more than 38% may have a current HCV infection [18]. Because of the prevalence and severity of these adverse outcomes, reducing harms associated with injection drug use is a growing clinical, scientific, and public health priority. Harm reduction is defined by the National Harm Reduction Coalition as “a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use (“Harm Reduction Principles,” n.d.).” Syringe service programs offer harm reduction interventions for people who inject opioids. Such interventions most often include provision of sterile injection equipment and education regarding ‘safer use practices’ intended to reduce the risk of accidental overdose and prevent the transmission of communicable disease [38, 50]. Research into the effectiveness of syringe service programs has been stymied by political, legal, social, and financial barriers to their implementation and sustainability [31]. Indeed, such constraints have been posited to limit the availability and effectiveness of these programs at reducing drug-related harms [40, 45]. Nevertheless, harm reduction services have been shown to prevent transmission of infectious diseases and accidental overdose among people who inject drugs, and research in this area has become a funding priority of the National Institute on Drug Abuse (NIDA) and Substance Abuse and Mental Health Service Administration (SAMHSA) (Abuse, 2022; [7],Harm [27, 41, 44]). The extent to which pain might interfere with adherence to safer injection practices for people who inject opioids is unknown. Pain is defined by the International Association for the Study of Pain (IASP) as “an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage [35].” This definition explicitly acknowledges the complexity of pain as multidimensional construct inclusive of a wide range of experiential domains and causal etiologies. Chronic pain is prevalent among individuals with opioid use disorder (OUD) and a recent study of syringe service program clients found that a majority of people who inject opioids perceived pain to be related to the onset, maintenance, and relapse of their OUD [42, 48]. Prior research has demonstrated an association between pain and non-medical opioid use among people who inject opioids [12]. However, to our knowledge, no study has explored whether increased pain intensity might influence the behavior of people who inject opioids such that they forgo learned safer injection practices to expedite pain relief. Pain-related negative urgency is believed to play an important role in the relationship between chronic pain and substance use [21]. Negative urgency refers to the tendency to act impulsively when distressed [21]. Given that negative urgency has been linked to a variety of harmful or risky behaviors, it is plausible that pain might motivate people who inject opioids to eschew learned safer injection practices [11, 16, 25]. If true, pain might be a previously unrecognized factor limiting engagement in and adherence to safer injection practices. By extension, linking people who inject opioids to evidence-based pain management might reduce their risk of accidental overdose and infectious complications of injection drug use. Therefore, this study aimed to determine if fluctuations in pain severity over the past 7 days were associated with changes in injection practices among people who inject opioids who had received standardized safer injection training. Specifically, we assessed whether adherence to safer use practices differed when pain was at its best and worst severity over the preceding 7 days. We hypothesized that participants would report lower adherence to safer injection practices during periods of worst pain compared to best pain. Materials and methods Setting This research was conducted at Equitas Health through their Safe Point program—a syringe service program in Columbus, Ohio—between July 25, 2023, and March 19, 2024. Safe Point provides comprehensive harm reduction services intended to prevent accidental overdose and transmission of infectious diseases. These services include syringe exchange, infectious disease screening, medical and behavioral health linkage, case management, and education regarding safer injection practices. Standardized safer injection education is provided in verbal and written form to all program clients by trained syringe service program staff. This education includes advising clients about specific behaviors to reduce their risk of infection and overdose (i.e., clean hands and skin prior to injection, avoid using alone, etc.). Participants Adult syringe service program clients (n = 191) who had previously received standardized safer use education were consecutively recruited for a larger study about substance use. Exclusion criteria for the larger study were inability to provide informed consent, read, or understand survey items. The present sub-analysis includes participants who endorsed injecting opioids (IV, IM, or SQ) 2 or more times per day and rated their average pain intensity 3 or more out of 10 over the past 7 days (n = 130). A pain threshold of 3/10 was selected to ensure adequate sample size while focusing on individuals experiencing pain that might reasonably influence injection behaviors. Procedures Recruitment was conducted by a trained Research Coordinator while syringe exchange program clients waited for harm reduction services. To reduce risk of bias, participants completed questionnaires in private and were not allowed to interact with one another while completing the survey. Survey data were collected in English using REDCap, a web platform designed for secure collection of personal health information and online database management [29]. Participants completed a screening battery assessing bodily pain and headache the Chronic Overlapping Pain Condition Screener (COPCS) [46]. They were then asked to rate the severity of their best, worst, and average pain over the past 7 days on a numerical rating scale from 0 (no pain) to 10 (worst pain imaginable) [20]. Participants then responded to a series of questions assessing their injection opioid use practices when their pain was at its best and worst severity. These questions were based on safer injection practices counseling and scored 1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always. Table 1 displays relevant questionnaire items. Table 1Questions regarding pain severity and injection practices during best pain and worst pain1. In the past 7 days, how would you rate your average pain?2. In the past 7 days, how would you rate your pain at its worst?3. In the past 7 days, how would you rate your pain at its best?4. When your pain is at its _*, as you rated above, how often do you…a. Clean your hands before injecting drugsb. Clean your skin at the site where you plan to inject drugsc. Reuse your own injection equipment (needles, syringes, filters, cookers, etc. you have injected with at least once before)d. Borrow used injection equipment, or share injection equipment with someone elsee. Wait to inject drugs until you can get to a place that is clean, and you feel safeResponses to questions 1–3 were rated on a 0 to 10 numeric scale with 0 indicating ‘no pain’ and 10 indicating ‘worst pain imaginable.’ Question 4 included sub-items a-e and was asked 3 separate times for best pain, worst pain and average pain. _* = best, worst, average. These sub-items were scored 1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always Questions regarding pain severity and injection practices during best pain and worst pain Responses to questions 1–3 were rated on a 0 to 10 numeric scale with 0 indicating ‘no pain’ and 10 indicating ‘worst pain imaginable.’ Question 4 included sub-items a-e and was asked 3 separate times for best pain, worst pain and average pain. _* = best, worst, average. These sub-items were scored 1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always Statistical analysis Descriptive statistics detailed sample characteristics as well as pain and substance use variables. A within-subjects analysis was conducted to determine whether participants’ adherence to safer injection practices varied with changes in pain severity (best pain and worst pain over the preceding 7 days). Paired self-report ratings of adherence to safer injection practices during best pain and worst pain were compared via Sign Test. The Sign Test is a non-parametric alternative to the paired sample t-test which is more statistically conservative than the Wilcoxon Signed-Rank Test for the type of data presented in this study. This analytical method was chosen due to its suitability for paired, ordinal data and ability to assess the direction of behavioral change (i.e., whether participants endorsed greater, or lesser adherence to safer injection practices under conditions of best and worst pain severity). Statistical significance was set at p < 0.05. To account for multiple comparisons across 7 outcomes, we used the Benjamini & Hochberg procedure to control the false discovery rate [5]. All analyses were performed with SPSS software Version 28.0. Ethics The study protocol (2022H0369) was approved by the Ohio State University Wexner Medical Center Institutional Review Board (Located: Columbus, Ohio, initial approval granted on 11/27/2022). Participants provided verbal consent and were monetarily compensated for their time. Results Sample characteristics Demographic information was given by 129 (99.2%) participants. The majority identified as White (n = 120, 92.3%), male (n = 78, 60.0%), and Non-Hispanic (126, 96.9%). On average, participants were 38.4 years old (SD = 8.5) and had used opioids for 17.0 years (SD = 8.0). Nearly all endorsed IV opioid use 128 (98.5%). Other injection opioid use was less common, with 13 (10%) reporting IM and 9 (6.9%) SQ opioid use. All participants included in this analysis injected (IV, IM, or SQ) opioids at least twice daily. The mean number of times participants used opioids daily was 5.4 (SD = 3.5). One hundred eleven (111, 85.4%) of participants met diagnostic criteria for at least one chronic pain condition [46]. The most common chronic pain condition in the sample was chronic low back pain (87, 66.9%). A comprehensive presentation of pain characteristics in this sample is available elsewhere [43]. Demographic and opioid use data are summarized in Table 2. Table 2Sample characteristicsCharacteristicParticipants (n = 130)Age mean (SD)Years38.4 (8.5)Sex assigned at birth n (%)Female52 (40.0)Male78 (60.0)Racial identity n (%)Black or African American8 (6.2)White or Caucasian120 (92.3)Native American or Alaskan Native6 (4.6)Native Hawaiian or Pacific Islander1 (0.8)Asian1 (0.8)Ethnicity n (%)Hispanic3 (2.3)Non-Hispanic126 (96.9)Age of first opioid use mean (SD)Years21.3 (8.2)OUD severity mean (SD)DSM-5 criteria10.2 (1.6)Route of administration n (%)Intravenous128 (98.5)Subcutaneous9 (6.9)Intramuscular13 (10.0)Smoking87 (66.9)Swallowing by mouth17 (13.1)Snorting / sniffing up the nose43 (33.1)Another Route4 (3.1)Monetary cost of daily opioid use mean (SD)US dollars85.4 (59.0)One participant was missing age, race and ethnicity data. Sixteen were missing data for monetary cost of daily opioid use Sample characteristics One participant was missing age, race and ethnicity data. Sixteen were missing data for monetary cost of daily opioid use Pain severity and adherence to safer injection practices Participants were asked to rate their pain at its best, worst, and average severity over the past 7 days on a 0–10 visual analog scale. Mean best pain severity was 4.8 (SD = 2.1). Mean average pain severity was 6.5 (SD = 2.1). Mean worst pain severity was 7.7 (SD = 1.9). Participants were also asked to report how often they engaged in specific injection practices when their pain was at its best and worst severity. Figure 1 displays mean self-reported frequency of injection practices under conditions of best and worst pain. Mean self-reported frequency of injection practices under conditions of best and worst pain Within subject differences in injection practices during best and worst pain A within-subjects Sign Test analysis revealed participants’ adherence to 5 of 7 safer injection practices fluctuated with changes in pain severity (best pain versus worst pain over the preceding 7 days). When their pain was at its worst, participants less often engaged in hand washing, cleaning the injection site, and waiting until in a clean safe place to inject. Additionally, participants were significantly more likely to reuse their own injection equipment, and inject faster, or at a higher dose when their pain was at its worst. No significant difference was observed in the frequency of borrowing, or sharing others’ injection equipment, or injecting alone when pain was at its worst relative to when pain was at its best. Table 3 displays the results of the within-subject analysis. Table 3Results of sign tests comparing injection practices during best pain and worst painBehaviorIncrease (n)Decrease (n)No change (n)Zp-valueClean hands before injection85369−5.63 < 0.001Clean skin at injection site105367−5.29 < 0.001Reuse injection equipment452362−2.550.011Borrow or share injection equipment271588−1.700.090Wait to inject until in a clean safe place154768−3.94 < 0.001Inject faster or use a higher dose411970−2.710.007Inject alone291784−1.620.105The Increase column contains the number of participants who increased the frequency of each behavior when their pain was at its worst severity. The Decrease column reflects the number of participants who engaged in each behavior less when their pain was at its worst severity. All significant findings remained significant after Benjamini–Hochberg correction (FDR = 0.05) Results of sign tests comparing injection practices during best pain and worst pain The Increase column contains the number of participants who increased the frequency of each behavior when their pain was at its worst severity. The Decrease column reflects the number of participants who engaged in each behavior less when their pain was at its worst severity. All significant findings remained significant after Benjamini–Hochberg correction (FDR = 0.05) Discussion This study provides initial evidence that pain is associated with reduced adherence to safer injection practices among people who inject opioids. Although all study participants received training in safer injection practices and cost-free sterile injection equipment, within-subject adherence to safer use practices varied significantly under conditions of best and worst pain. When their pain was at its worst, participants reported they were more likely to engage in behaviors placing them at increased risk of infectious complications of injection opioid use and accidental overdose. These findings suggest pain may be a previously overlooked factor increasing risks associated with injection opioid use and a potential target for behavioral interventions to improve adherence to safer injection counseling among syringe service program clients. The public health burden associated with injection drug use has been described as a ‘crisis’ [34, 51]. The prevalence of injection drug use in the United States is likely underestimated, but 1,000,000 Americans may engage in injection drug use annually [6, 34]. These individuals are at increased risk of accidental overdose, as well as life-threatening infectious complications including viral, bacterial, and fungal infections of the skin, soft tissue, osteoarticular joint spaces, eyes, blood, liver, and heart [36]. The Infectious Disease Society of America (IDSA) and the HIV Medicine Association have called for expansion of harm reduction programs and services to address this crisis [34]. Convergent evidence demonstrates syringe service programs reduce transmission of infectious disease and prevent overdose [4, 22, 39]. However, little is known about factors that might increase the risk of poor outcomes among syringe service program clients or limit adherence to the safer injection practices they teach. Prior research linking pain, impulsivity, and risk taking provides context to the present findings. Pain is a cognitively demanding experience and therefore may impair other cognitive processes like decision making [47]. Participants in the present study reported decreased adherence to safer injection practices when their pain was more severe, possibly reflecting impaired decision making under the increased cognitive load imposed by worsening pain. Indeed, experimentally induced acute pain increases other impulsive risk-taking behavior among healthy adults [32]. Aligning with our observations, individuals with chronic pain exhibit disrupted risk decision-making when compared to healthy adults [30]. Additionally, impulsivity, especially negative urgency, or the tendency to act impulsively when distressed, has been associated with opioid misuse and symptoms of OUD among people with chronic pain [21, 52]. Pain has also been shown to negatively impact quality of life among syringe service clients [15]. Together, this prior research provides a potential explanation of why many participants in the present study eschewed learned safer injection practices when their pain intensity increased. However, to our knowledge, no prior study has examined how pain might impair risk decision-making among people with OUD, or people who inject drugs. Our report contributes to the literature by showing that pain severity might affect risk decision making among people who inject opioids, possibly leading to more frequent engagement in behaviors associated with life threatening infections and accidental overdose. The present study had notable limitations. Due to practical and ethical considerations, injection opioid use could not be directly observed. Self-report measures are susceptible to memory errors. Consistent with existing self-report pain surveys, we attempted to minimize memory errors by limiting the recall window to 7 days [3, 8]. Additionally, this study used a cross-sectional design, eliminating the opportunity for determining causal or temporal relationships between pain and injection opioid use. Specific domains of impulsivity, including negative urgency, were not directly assessed. Nevertheless, a growing body of literature substantiates the role of negative urgency in the relationship between pain and substance use as well as other risky behaviors [16, 21, 24, 37, 52]. Although participants completed a validated questionnaire screening for a variety of chronic pain conditions (COPCS), the etiology of pain was not assessed by clinician evaluation or by medical record review. Among people with OUD, reports of pain may relate to disease, injury, symptoms of opioid hyperalgesia, opioid withdrawal and related negative affective urgency, or a combination of etiologies. However, according to the IASP’s definition of pain, “a person’s report of an experience of pain should be respected” regardless of etiology, or where in the body or nervous system it might arise [35]. This assertion is especially salient in harm reduction research and clinical practice. Nevertheless, more thorough assessment of specific pain etiologies would have substantially strengthened our study as the present design could not determine whether specific pain mechanisms differentially contributed to reduced adherence to safer injection practices. Finally, participants were recruited from a single syringe service program and were predominantly White, non-Hispanic, and male. English-only data collection may limit generalizability. Future research should replicate and extend the present work while accounting for its limitations. Longitudinal observational research should explore pain as one possible factor reducing adherence to safer injection practices and examine pain-related negative urgency as a potential target for behavioral intervention among syringe service program clients. The addition of medical and psychological pain treatments to syringe service programs should be tested as a possible means to reduce harms of injection opioid use. Current best practices for treatment of chronic pain includes a personalized, multimodal, interdisciplinary treatment approach consisting of a combination of medications, psychological interventions, integrative therapies, and procedures [9]. There is growing evidence for psychological interventions in the treatment of chronic pain in adults [13, 14, 19]. The efficacy and optimal delivery of these interventions for people who inject opioids is unknown. However, syringe service programs already provide linkage to a variety of health services (i.e., vaccinations, primary care, mental health services, etc.) [2]. Therefore, referral to pain treatment would align with the existing scope of these programs. In conclusion, this study offers initial evidence that fluctuations in pain intensity may be associated with changes in adherence to safer use practices among people who inject opioids. A within-subjects analysis revealed that participants were less adherent to safer use practices when their pain was worse. To our knowledge, no prior study has shown pain to motivate higher risk injection practices among people who inject opioids. Given the tremendous public health burden associated with injection drug use, pain should be explored as a potential target for interventions to increase adherence to safer use practices among people who inject opioids. Acknowledgements Not applicable Abbreviations Subcutaneous Intramuscular Intravenous Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome Hepatitis B virus Hepatitis C virus National Institute on Drug Abuse Substance Abuse and Mental Health Service Administration Opioid use disorder Author contributions OTH conducted statistical analyses. All authors were major contributors to drafting and editing the manuscript. Funding None. Data availability Data used in this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate The study protocol (2022H0369) was approved by the Ohio State University Wexner Medical Center Institutional Review Board (Located: Columbus, Ohio, initial approval granted on 11/27/2022). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data used in this study are available from the corresponding author upon reasonable request.